Subsequently, more studies confirmed this phenomenon and found that PRL-3 was highly expressed in other primary and metastatic tumors, including gastric cancer [59,60,61], colorectal cancer [62,63], breast cancer [42,64], liver cancer [43,65], intrahepatic cholangiocarcinoma [66], lung cancer [67,68], esophageal cancer [69], nasopharyngeal carcinoma [70], uveal melanoma [71], ovarian and cervical carcinoma [72,73]. This evidence concerns the gene PTP4A3 and liver cancer.